Tesamorelin — The Only FDA-Approved GHRH Analog
Fifteen years of human safety data. Phase III trials. The most clinically validated GHRH analog available. No marketing hype — just what the evidence actually says.
15–18%
Visceral fat reduction at 26 weeks (Phase III)
2010
FDA approval year — 15 years of human safety data
44
Amino acids in the tesamorelin molecule
32
States served — legal, physician-prescribed
Tesamorelin is a 44-amino-acid synthetic analog of growth-hormone-releasing hormone (GHRH). It was FDA-approved in 2010 (Egrifta, NDA 22-505) for reducing visceral adipose tissue — a Phase III clinical program that produced the strongest visceral fat reduction data available for any peptide: 15–18% reduction in visceral fat at 26 weeks at 2mg/day. At VitalRx, tesamorelin is offered as a physician-supervised monthly protocol — pre-constituted, ready to inject, with 28-day lab monitoring included at every step. This page tells you what tesamorelin can and cannot do, what realistic results look like on clinical timelines, what the evidence says about cycling, and what the true all-in cost comparison is. If a claim is not backed by clinical evidence, we say so.
What Tesamorelin Actually Is
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH). It binds to GHRH receptors in the anterior pituitary gland and triggers the natural, pulsatile release of growth hormone — it does not inject GH directly. This distinction is clinically important: pulsatile GH release preserves the body's somatostatin feedback mechanisms, unlike exogenous HGH which bypasses them entirely. It was FDA-approved in November 2010 under the brand name Egrifta (NDA 22-505) for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy — the Phase III program that generated 15–18% reduction in visceral adipose tissue (VAT) after 26 weeks at 2mg/day.
What Tesamorelin Does NOT Do
Tesamorelin does not reduce subcutaneous fat — the fat you can pinch. It targets visceral fat: the deep abdominal fat surrounding your organs. If your goal is purely aesthetic belly fat loss, your results may be limited or invisible in the mirror even when the metabolic benefits are real. This distinction is almost never explained clearly by vendors or influencers.
The Secondary Benefit Most Sources Undersell
Clinical data shows tesamorelin significantly reduces liver fat (hepatic steatosis), improves triglyceride levels, and has demonstrated cognitive benefits in older adults. For metabolic health — not just aesthetics — the evidence is compelling even when mirror changes are subtle.
How Tesamorelin Works
GHRH Receptor Binding and Pulsatile GH Release
Tesamorelin binds to GHRH receptors in the anterior pituitary and stimulates natural, pulsatile GH release. GH then triggers the liver to produce IGF-1, which drives downstream metabolic effects — most notably lipolysis in visceral adipose tissue. The somatostatin system still applies the brakes. This is why tesamorelin's side effect profile is significantly more favorable than synthetic HGH, and why IGF-1 levels typically stay within physiological ranges rather than spiking to supraphysiological levels.
Why Tesamorelin for Visceral Fat vs. CJC-1295
Tesamorelin's molecular structure mirrors endogenous GHRH more closely than CJC-1295, producing cleaner receptor binding without the prolonged half-life that blunts natural pulsatility. For visceral fat reduction specifically, the clinical data behind tesamorelin is superior to any other GHRH analog — it is the only one with Phase III randomized controlled trials and an FDA approval for this indication.
Tesamorelin vs. Exogenous HGH
Exogenous HGH bypasses the pituitary entirely, suppresses the GH axis, and produces supraphysiological IGF-1 associated with joint pain, water retention, insulin resistance, and pituitary axis suppression. Tesamorelin's pituitary-mediated mechanism produces GH release that remains feedback-regulated. The physiological profile and safety margins are meaningfully different — tesamorelin is not a substitute for HGH. It is a pharmacologically distinct FDA-approved compound.
Who Tesamorelin Is Actually For
Off-label, tesamorelin is used across four patient profiles. Understanding which profile matches you determines whether it is the right choice — and what realistic success looks like.
Metabolic Optimizer
Male, 35–55, often on TRT
Primary Goal: Visceral fat reduction, body recomposition, IGF-1 optimization
Tesamorelin's visceral fat reduction mechanism is most directly relevant here. Men in this age range with elevated visceral adiposity are the closest analog to the Phase III trial population. The synergy with testosterone therapy — which reduces visceral adiposity through different mechanisms — makes the combination common in clinical practice.
Anti-Aging Biohacker
Mixed gender, 45–65
Primary Goal: Longevity protocol, skin quality, sleep improvement, metabolic health
GH decline is one of the most consequential hormonal changes of aging — tesamorelin addresses it at the pituitary signaling level. Beyond visceral fat, improvements in sleep quality, skin collagen, IGF-1-driven tissue repair, and the hepatic and triglyceride benefits represent meaningful longevity protocol contributions. This profile typically values the 15 years of human safety data more than other profiles.
Performance Athlete
Male, 25–40, bodybuilding focus
Primary Goal: Fat loss during cut, lean mass preservation
Tesamorelin can contribute to a cutting protocol through visceral fat reduction and IGF-1-driven lean mass preservation. Athletes expecting dramatic subcutaneous fat loss or rapid visible changes should recalibrate — the compound works on visceral fat, and the timeline to measurable response is 8–16 weeks minimum. For athletes with significant baseline visceral fat and a 6-month horizon, fit is strong. For those expecting results in 4–6 weeks, fit is poor.
Aesthetic-Only Goals
Primary goal: visible belly fat loss
Primary Goal: External subcutaneous fat reduction
Tesamorelin does not reduce subcutaneous fat in clinical trials. If the primary goal is visible reduction of the fat you can see and pinch, tesamorelin is not the primary tool. Its benefits are metabolic — visceral fat, triglycerides, liver fat — largely invisible in the mirror.
What Tesamorelin Can Do
Visceral Fat Reduction
15–18% reduction in visceral adipose tissue at 26 weeks at 2mg/day in Phase III randomized controlled trials. Visceral fat — the metabolically active fat surrounding the abdominal organs — not subcutaneous fat.
Phase III RCT — strongest available evidence classTriglyceride and Lipid Improvement
Clinical data consistently shows significant triglyceride reduction — one of the most reliable metabolic benefits and a useful secondary signal that the compound is working. Meaningful cardiovascular risk reduction.
Phase III RCT secondary endpoint — well-establishedHepatic Fat Reduction
Tesamorelin reduces liver fat (hepatic steatosis) — a clinically significant benefit for the metabolic optimizer population where NAFLD is a common comorbidity.
Clinical trial data — established benefitIGF-1 Optimization
Reliably elevates IGF-1 — the downstream hormone through which GH exerts most of its anabolic and metabolic effects. Drives lean mass preservation, tissue repair, and metabolic optimization. IGF-1 rise is also the primary lab marker confirming the compound is working, measurable at 4 weeks.
Primary efficacy marker — well-establishedCognitive Benefits in Older Adults
Demonstrated improvements in executive function and memory in clinical research. Likely mediated by IGF-1's neurotrophic effects — an undersold benefit relative to the body composition focus of most marketing.
Clinical research — emerging but substantiatedSleep Quality Improvement
Many patients report improved sleep depth and recovery quality in early weeks. Likely related to GH's role in slow-wave sleep architecture. Often among the earliest subjective benefits reported.
Patient-reported — consistent across clinical populationsRealistic Expectations — Honestly
The biggest frustration with tesamorelin is calibration failure — expecting results in 4 weeks when the molecule requires 3–6 months. The following timeline matches the clinical data.
Early Adaptation
Some patients notice improved sleep quality and mild water retention. No measurable fat changes. Any source claiming visible results in 1–2 weeks is overstating the evidence.
IGF-1 Response
IGF-1 levels should be rising measurably — confirmed by lab. This is the first confirmation the compound is working. Subcutaneous appearance is unlikely to change yet. Do not assess effectiveness at this stage.
Metabolic Shift
Some patients begin noticing waistline changes, particularly those with significant baseline visceral fat. Triglyceride and liver enzyme improvements may appear in labs. Skin quality improvements frequently reported.
Minimum Assessment Point
First meaningful assessment of effectiveness. Clinical trials show measurable VAT reduction between 8–16 weeks. If no IGF-1 response or subjective change by week 12, discuss with your VitalRx provider before continuing.
Full Clinical Effect
Phase III data shows peak VAT reduction at 26 weeks. The 15–18% number comes from this timepoint. This is the minimum timeframe to fully evaluate your tesamorelin response.
The Non-Responder Reality Nobody Discloses
Approximately 31% of Phase III trial participants did not achieve the primary endpoint of ≥8% visceral fat reduction. Non-response is real. If you are three months in with confirmed IGF-1 elevation and no measurable change, you may be a non-responder — and that is not a sourcing problem or a dosing problem. It is biology. Your VitalRx provider will help you evaluate this and discuss alternatives.
Fat Returns When You Stop — The Actual Timeline
Clinical data confirms visceral fat reaccumulates within approximately 12 weeks of discontinuation. Tesamorelin is a maintenance therapy, not a permanent transformation. When the stimulus stops, the effect reverses. Plan accordingly.
Dosing Protocol
The FDA-approved dose is 2mg subcutaneously once daily. Not weight-based — the Phase III trials used a fixed dose across the entire participant population. Weight-adjusted dosing calculators in the community have no clinical basis.
| Context | Dose | Timing | Evidence |
|---|---|---|---|
| FDA-Approved Protocol | 2mg/day | Once daily, any time | Phase III RCT |
| VitalRx Clinical Protocol | 1mg/day (Month 1); 2mg/day (Month 2+) | Before bed preferred — aligns with natural GH pulsatility | Evidence-based clinical practice |
| Telehealth Reduced-Dose | 0.5–1mg/day | Varies | Community-derived — no clinical superiority evidence |
| Weight-Based Calculators | Variable formulas | Various | No clinical basis — not endorsed by VitalRx |
FDA-Approved Protocol
Dose
2mg/day
Timing
Once daily, any time
Evidence
Phase III RCT
VitalRx Clinical Protocol
Dose
1mg/day (Month 1); 2mg/day (Month 2+)
Timing
Before bed preferred — aligns with natural GH pulsatility
Evidence
Evidence-based clinical practice
Telehealth Reduced-Dose
Dose
0.5–1mg/day
Timing
Varies
Evidence
Community-derived — no clinical superiority evidence
Weight-Based Calculators
Dose
Variable formulas
Timing
Various
Evidence
No clinical basis — not endorsed by VitalRx
The VitalRx Difference
Your VitalRx physician determines your starting dose and adjusts based on 28-day IGF-1 results. Month 1 intentionally starts at 1mg/day — not 2mg. This confirms your IGF-1 response, catches early side effects, and establishes your individual baseline. If you are a non-responder, we identify that at $449, not after six months at full dose.
Injection Guidance
Injection Site
Subcutaneously into abdominal fat — rotate sites within the abdomen to avoid scar tissue buildup
Avoid
Avoid the 2-inch zone around the navel
Syringes
Standard insulin syringes (28–31g, 6mm–8mm)
Temperature
Allow reconstituted solution to reach room temperature before injecting to reduce injection site discomfort
Cycling — What the Evidence Actually Says
The cycling debate is one of the most contentious and misinformation-heavy topics in the tesamorelin community.
FDA Phase III trials ran continuous daily tesamorelin for 26–52 weeks with no cycling protocol. There is no published clinical evidence supporting cycling for receptor desensitization prevention. The cycling rationale — that pituitary receptors downregulate with continuous use — is a theoretical concern borrowed from GHRP pharmacology and has not been demonstrated in tesamorelin-specific human studies.
Influencer-derived cycling protocols range from 5-days-on/2-off to 12-weeks-on/8-weeks-off, with no consensus. The disagreement itself is diagnostic: if there were clinical data supporting a specific cycling pattern, everyone would cite the same study. The variation reflects extrapolation from other peptides (CJC-1295, GHRP-6) onto tesamorelin — which has a different pharmacological profile and a much stronger evidence base.
Cycle off to prevent receptor desensitization
Theoretical — no tesamorelin-specific human data5-on/2-off preserves pulsatility
Community-derived — no clinical support12 weeks on / 8 weeks off
No published basis for this ratioContinuous daily use (FDA protocol)
Phase III RCT — 26–52 weeks continuous. The evidence-supported approach.VitalRx Position
Cycling protocol — if any — is determined by your physician based on your labs and individual response. Generic internet cycling protocols are not applied to patients with individual physiologies.
Ready to Inject. No Mixing Required.
Most peptide vendors ship dry lyophilized powder and leave patients to reconstitute it from a Reddit thread. VitalRx ships tesamorelin pre-constituted and ready to inject. Vials arrive from the 503B pharmacy already mixed to your prescribed concentration, cold-packed, and labeled with your exact prescribed dose.
What You Get
- Pre-constituted at your prescribed concentration — no calculations required
- Cold-chain maintained from pharmacy to your door
- Label shows your exact dose in plain language
- Zero mixing steps required — the most common peptide preparation error is eliminated before shipment
In Your Shipment
- •Pre-constituted tesamorelin vials at prescribed concentration
- •Insulin syringes (28–31g)
- •Alcohol prep pads
- •Sharps disposal container
- •Printed dosing card specific to your prescription
Storage
Refrigerate at 36–46°F (2–8°C) immediately upon receipt, protected from light. Use within 28 days of the pharmacy preparation date. Never freeze.
Lyophilized (dry powder) format is also available for patients with specific storage needs. If using dry powder: bacteriostatic water (BAC water, 0.9% benzyl alcohol) — not sterile water — is required. For a 15mg vial to 2mg/mL: add 7.5mL BAC water slowly down the side of the vial, swirl gently (never shake), and refrigerate. Contact your VitalRx provider for your specific concentration instructions before reconstituting.
Lab Monitoring Protocol — Every 28 Days
VitalRx requires labs before starting and every 28 days. No other telehealth peptide service requires this monitoring frequency.
Why Every 28 Days?
Most clinics run baseline labs and check in at 3 months. VitalRx monitors every 28 days because that is when early signals are catchable — a glucose creeping up, IGF-1 not responding, or a triglyceride improvement confirming the treatment is working. This is the clinical foundation that makes the protocol safe and individualized rather than generic.
IGF-1 (Insulin-like Growth Factor-1)
Primary Efficacy MarkerTarget: Upper 1/3 of age-adjusted normal range
Primary indicator the compound is working. Should rise measurably by week 4. If not, physician evaluates dose, timing, storage compliance, and non-response. Supraphysiological levels (above range) prompt dose reduction.
Fasting Glucose + HbA1c
Safety MarkerTarget: Fasting glucose <100 mg/dL
GH elevation can cause insulin resistance. Tesamorelin's prescribing information includes glucose monitoring. Monitored every 28 days — not just at baseline. Diabetes or pre-diabetes at baseline requires careful evaluation before starting.
Lipid Panel (Triglycerides, LDL, HDL)
Safety + Secondary Efficacy MarkerTarget: Triglyceride improvement expected; worsening warrants evaluation
Tesamorelin consistently improves triglycerides in clinical trials — a reliable secondary efficacy signal. Worsening lipids are a flag for clinical evaluation.
Liver Enzymes (AST/ALT)
Safety MarkerTarget: Within normal limits
GH pathways interact with hepatic metabolism. Catches early liver stress signals, particularly relevant in patients with baseline NAFLD.
Thyroid Panel (TSH, Free T4)
Contextual MarkerTarget: Within normal limits
GH therapy can unmask subclinical hypothyroidism. Evaluated when patients do not respond as expected or experience unusual fatigue.
Cortisol (AM)
Contextual MarkerTarget: 7–20 mcg/dL (AM)
GH and cortisol interact metabolically. Abnormal cortisol can blunt fat-loss effects and may indicate underlying HPA axis dysfunction worth addressing separately.
Stacking with Ipamorelin
VitalRx offers a Tesamorelin + Ipamorelin stack as a combined protocol — one of the most logical pairings in the GHRH/GHRP category. Tesamorelin is a GHRH analog: it tells the pituitary to release GH. Ipamorelin is a GHRP (ghrelin receptor agonist) that amplifies GH pulses through a completely independent receptor pathway. Combined, they stimulate GH release through two pathways simultaneously. Research shows GHRH + GHRP combinations produce approximately 2–4x the GH release of either compound individually. Among GHRPs, ipamorelin has the most selective GH release profile — minimal cortisol or prolactin elevation compared to GHRP-6 or GHRP-2 — making it a cleaner stack partner.
Monitoring Note
When running the combination stack, IGF-1 monitoring is even more important. The synergistic GH pulse can push IGF-1 higher than either compound alone. The 28-day lab protocol is designed to catch supraphysiological IGF-1 levels early and adjust dosing accordingly.
Tesamorelin at VitalRx — Protocol Pricing
VitalRx offers tesamorelin as an all-inclusive monthly protocol — medication, physician oversight, labs, supplies, and shipping in a single flat rate. No hidden fees. No separate lab invoice. No surprise supply charges.
Many telehealth clinics advertise a monthly medication price — then bill labs, physician consultations, and supplies separately. The number that matters is the total monthly cost. VitalRx builds everything into one number.
VitalRx Tesamorelin Protocol — Month 1 (Titration, All-In)
$449
1mg/day (titration phase)
28-day titration protocol at 1mg/day. Confirms IGF-1 response, establishes individual baseline, catches early side effects before committing to full-protocol dosing. If you are a non-responder, this is where we identify that — not after six months at full dose. Pre-constituted vials, 503B-sourced, physician-labeled, cold-chain shipped.
- Pre-constituted tesamorelin medication (28-day supply at 1mg/day)
- Licensed physician evaluation and prescription
- Baseline lab panel — IGF-1, fasting glucose, HbA1c, lipids, liver enzymes, thyroid, cortisol
- FedEx Standard Overnight cold-chain shipping
- Insulin syringes, alcohol prep pads, sharps container, dosing card
VitalRx Tesamorelin Protocol — Month 2+ (Full Protocol, All-In)
$664
6-month: $3769
2mg/day (FDA-approved dose)
28-day full protocol at 2mg/day — the FDA-approved clinical dose. Monthly physician review and 28-day lab panel at every cycle. Pre-constituted, 503B-sourced, cold-chain shipped. 6-month all-in total: $3,769.
- Pre-constituted tesamorelin medication (28-day supply at 2mg/day)
- Monthly licensed physician review and protocol adjustment
- Monthly 28-day lab panel — IGF-1, fasting glucose, HbA1c, lipids, liver enzymes, thyroid, cortisol
- FedEx Standard Overnight cold-chain shipping
- Insulin syringes, alcohol prep pads, sharps container, dosing card
Tesamorelin + Ipamorelin Combination Stack — 5mL
$258.33
Physician-determined based on combination protocol
Tesamorelin 2.4mg/mL + Ipamorelin 1.2mg/mL per mL, 5mL vial. Dual-pathway GH stimulation — GHRH receptor agonism paired with ghrelin receptor amplification. Approximately 2–4x GH release vs. either compound alone. Prescription required. Compounded by Optimal Balance Pharmacy. Monthly all-in protocol pricing (including physician and labs) discussed with your provider.
- Pre-constituted combination vial (5mL)
- Async telehealth provider consultation
- FedEx Standard Overnight cold-chain shipping
- Syringes, alcohol prep pads
How VitalRx Compares
| Pathway | Monthly Cost | What's Included | Quality |
|---|---|---|---|
| Brand Egrifta (retail, no insurance) | ~$9,000–$10,673 | Medication only. Labs, physician, supplies billed separately. | FDA Brand Drug |
| Other Telehealth Clinics | From $199/mo advertised | Advertised price typically covers medication only. Lab requirements, consultation fees, and supplies rarely disclosed upfront. | Varies by Clinic |
| VitalRx Month 1 (1mg/day titration) | $449 | Pre-constituted medication + physician + labs + cold-chain shipping + supplies. Everything included. | 503B Pharma-Grade |
| VitalRx Month 2+ (2mg/day full protocol) | $664 | Pre-constituted medication + physician + labs + cold-chain shipping + supplies. Everything included. | 503B Pharma-Grade |
| Gray Market / Research Grade | $100–$350 | Dry powder only. No physician. No labs. No quality guarantee. Independent purity testing: top vendors scored as low as 4.9/10. | Unverified |
Brand Egrifta (retail, no insurance)
~$9,000–$10,673
Included: Medication only. Labs, physician, supplies billed separately.
Quality: FDA Brand Drug
Other Telehealth Clinics
From $199/mo advertised
Included: Advertised price typically covers medication only. Lab requirements, consultation fees, and supplies rarely disclosed upfront.
Quality: Varies by Clinic
VitalRx Month 1 (1mg/day titration)
$449
Included: Pre-constituted medication + physician + labs + cold-chain shipping + supplies. Everything included.
Quality: 503B Pharma-Grade
VitalRx Month 2+ (2mg/day full protocol)
$664
Included: Pre-constituted medication + physician + labs + cold-chain shipping + supplies. Everything included.
Quality: 503B Pharma-Grade
Gray Market / Research Grade
$100–$350
Included: Dry powder only. No physician. No labs. No quality guarantee. Independent purity testing: top vendors scored as low as 4.9/10.
Quality: Unverified
All products require a valid prescription. Provider consultation is included with your protocol.
Legal Access Across 32 States and D.C.
This is what separates tesamorelin from almost every other peptide in the optimization ecosystem. The 2024 FDA restrictions affected 19 peptides. Tesamorelin was not among them.
FDA Approval
Tesamorelin is the only FDA-approved GHRH analog in the United States (Egrifta, NDA 22-505, 2010). Phase III RCTs completed. Active New Drug Application on file. Patients receiving tesamorelin through VitalRx receive a physician-prescribed, FDA-approved drug — not a research chemical.
What the 2024 Restrictions Did
Between 2023 and December 2024, the FDA moved 19 peptides to Category 2 of the 503A Interim Bulks List — prohibiting their compounding. The list included CJC-1295, Ipamorelin, BPC-157, Thymosin Alpha-1, and others. Tesamorelin was not placed on this list. As an FDA-approved drug, it exists in a separate regulatory category the restrictions did not touch.
503B Outsourcing Facility Standard
VitalRx sources tesamorelin from a 503B FDA-registered outsourcing facility operating under pharmaceutical cGMP standards — the same standards applied to commercial drug manufacturers. This is categorically different from 503A compounding pharmacies and from research-use-only vendors.
Off-Label Prescribing Is Fully Legal
Tesamorelin's FDA approval is for HIV-associated lipodystrophy. Off-label prescribing — a physician prescribing an FDA-approved medication for a purpose not listed on the label — is a completely standard and legal medical practice across virtually every specialty. A VitalRx prescription is legal, documented, and medically supervised.
Gray Market Warning
Independent third-party testing has revealed that gray-market 'research use only' tesamorelin from the community's most-trusted vendors has scored as low as 4.9/10 on purity assays. Severely underdosed or impure product means patients may be injecting something with little to no active ingredient — or worse, contaminants. The 503B sourcing standard VitalRx uses eliminates this risk category.
How to Get Started with Tesamorelin at VitalRx
Choose Your Starting Protocol
Most patients start with the Month 1 Titration Protocol at 1mg/day ($449 all-in). This confirms your IGF-1 response and establishes your baseline before full-protocol commitment. If you want to include the Ipamorelin stack from the start, your provider will evaluate this during your consult.
Complete Your Async Consult
Answer a brief health intake at your own pace — no video call, no waiting room. Include your health history, current medications (especially TRT, diabetes medications, or prior peptide use), and primary goals. A licensed physician reviews your submission and issues your prescription and protocol. The provider consultation is included with your order.
Receive and Begin — With Labs Built In
Your pre-constituted vials, syringes, alcohol preps, sharps container, and personal dosing card ship via FedEx Standard Overnight, cold-packed. Your 28-day lab check is built into the protocol. Set the right evaluation horizon: week 4 confirms IGF-1 response, week 12 is the minimum fat-change assessment point, week 26 is the full clinical effect horizon.
Prescription required. Provider consultation included. 503B pharmacy-sourced. Legal across 32 states and D.C.
Related Treatments
CJC-1295 / Ipamorelin →
The alternative GHRH/GHRP combination for GH optimization. CJC-1295 has a longer half-life and different binding profile. For visceral fat reduction specifically, tesamorelin's Phase III data is superior. CJC-1295/Ipamorelin remains the more widely used general GH optimization stack.
Sermorelin →
The shorter-acting GHRH analog — a lower-cost starting point for patients entering GH secretagogue therapy. Tesamorelin has a significantly stronger evidence base for visceral fat; sermorelin is a more modest GH optimization option.
IGF-1 LR3 →
Direct IGF-1 supplementation — bypasses the pituitary axis to deliver downstream GH effects directly. For patients who want IGF-1 elevation without GHRH pathway dependence.
Ibutamoren (MK-677) →
Oral GH secretagogue — ghrelin receptor agonism without injection. Less potent than the Tesamorelin + Ipamorelin combination but a convenient GH secretagogue for patients who prefer oral administration.
Growth Hormone Peptides — Full Category →
Compare all GH secretagogue options at VitalRx — tesamorelin, sermorelin, CJC-1295/Ipamorelin, ibutamoren — in one place.
Community Q&A — Honest Answers
The questions asked most across the peptide community — answered without hedging or marketing spin.
The content on this page is for informational purposes only and does not constitute medical advice. Tesamorelin is a prescription-only medication. FDA approval is for HIV-associated lipodystrophy; off-label use requires a prescription from a licensed provider. Individual results vary. Approximately 31% of Phase III participants did not achieve the primary fat reduction endpoint. Consult a licensed healthcare provider before beginning any hormone or peptide therapy protocol.